“Efficacy and Safety of Adalimumab Biosimilar GP2017 in a 24-Month Treatment Period for Plaque Psoriasis: Real-Life Experience from Emilia-Romagna Centers, Italy”. Dermatology Reports (July 1, 2025). Accessed August 4, 2025. https://journals.pagepress.org/dr/article/view/10315.